Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
If everyone on Earth sat in the ocean at once, how much would sea level rise? - 2Cheetos and Doritos to launch new versions without artificial dyes
- 3Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- 4'Home Alone' actor Joe Pesci said 'no' to this stunt until he saw a 9-year-old girl do it, says director Chris Columbus
- 5Innovative Versatility: Examples of overcoming adversity from Entrepreneurs
- NASA's Perseverance Mars rover could break the record for miles driven on another planet
- Mom warns of Christmas gift hazard as daughter recovers in hospital
- New Jordan security fence could be done in early 2028
- IDF uncovers 7 km.-long Gaza terror tunnel where Hamas held Hadar Goldin
- Is new Harry Styles music on the way? Fans think so, after a cryptic website and posters pop up.
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis
- Heartfelt Objections to Visit with Your Adored One
- Flu surges across U.S. as doctor visits reach highest level since 1997
